Aaron Y. Kluger
YOU?
Author Swipe
View article: Contents
Contents Open
View article: Usefulness of Statins as Secondary Prevention Against Recurrent and Terminal Major Adverse Cardiovascular Events
Usefulness of Statins as Secondary Prevention Against Recurrent and Terminal Major Adverse Cardiovascular Events Open
Clinical guidelines recommend statins for patients with atherosclerotic cardiovascular disease (ASCVD), but many remain untreated. The goal of this study was to assess the impact of statin use on recurrent major adverse cardiovascular even…
View article: Trends in post–heart transplant biopsies for graft rejection versus nonrejection
Trends in post–heart transplant biopsies for graft rejection versus nonrejection Open
With alternatives such as gene profiling available for surveillance after orthotopic heart transplantation, we sought to evaluate the utilization of endomyocardial biopsies (EMBs) for hospitalized patients after heart transplantation. Surv…
View article: Benefits and Risks of Continuing Angiotensin-Converting Enzyme Inhibitors, Angiotensin II Receptor Antagonists, and Mineralocorticoid Receptor Antagonists during Hospitalizations for Acute Heart Failure
Benefits and Risks of Continuing Angiotensin-Converting Enzyme Inhibitors, Angiotensin II Receptor Antagonists, and Mineralocorticoid Receptor Antagonists during Hospitalizations for Acute Heart Failure Open
Background: The renin-angiotensin-aldosterone axis plays a pivotal role in the pathophysiology of acute and chronic heart failure (HF) and represents an important target for guideline-directed medical therapy. Summary:<…
View article: Continuation of Chronic Heart Failure Therapies During Heart Failure Hospitalization - a Review
Continuation of Chronic Heart Failure Therapies During Heart Failure Hospitalization - a Review Open
Randomized controlled trials have demonstrated the benefits of guideline-directed medical therapy in the outpatient setting for treatment of chronic heart failure. However, the benefits of continuation (or discontinuation) of major chronic…
View article: Class effects of SGLT2 inhibitors on cardiorenal outcomes
Class effects of SGLT2 inhibitors on cardiorenal outcomes Open
View article: Impact of Renal Dysfunction on Periprocedural Outcomes in Patients with Ischemic Cardiomyopathy Undergoing Elective Percutaneous Coronary Intervention (PCI)
Impact of Renal Dysfunction on Periprocedural Outcomes in Patients with Ischemic Cardiomyopathy Undergoing Elective Percutaneous Coronary Intervention (PCI) Open
View article: Impact of Renal Dysfunction on Patients Undergoing Left Ventricular Assist Device Implantation
Impact of Renal Dysfunction on Patients Undergoing Left Ventricular Assist Device Implantation Open
View article: Statin Update: Intolerance, Benefit, and Beyond
Statin Update: Intolerance, Benefit, and Beyond Open
View article: Supplementary Material for: The Effects of SGLT2 Inhibitors on Cardiovascular and Renal Outcomes in Diabetic Patients: A Systematic Review and Meta-Analysis
Supplementary Material for: The Effects of SGLT2 Inhibitors on Cardiovascular and Renal Outcomes in Diabetic Patients: A Systematic Review and Meta-Analysis Open
Background: Previous meta-analyses demonstrated the benefits of sodium-glucose cotransporter 2 inhibitors (SGLT2i) primarily on patients with established atherosclerotic cardiovascular disease (ASCVD), but with questionable e…
View article: Cardiovascular Disease in Patients with Chronic Kidney Disease
Cardiovascular Disease in Patients with Chronic Kidney Disease Open
View article: Alteration of lipid metabolism in chronic kidney disease, the role of novel antihyperlipidemic agents, and future directions
Alteration of lipid metabolism in chronic kidney disease, the role of novel antihyperlipidemic agents, and future directions Open
The role of anti-hyperlipidemic therapy remains of key importance in the treatment of atherosclerotic disease. Moreover, given an already exaggerated predisposition for vascular disease at baseline, there is a preponderance of data that sh…
View article: Cardiorenal Outcomes in the CANVAS, DECLARE-TIMI 58, and EMPA-REG OUTCOME Trials: A Systematic Review
Cardiorenal Outcomes in the CANVAS, DECLARE-TIMI 58, and EMPA-REG OUTCOME Trials: A Systematic Review Open
In this systematic review, we sought to summarize the 3 recent sodium-glucose cotransporter 2 inhibitor (SGLT2i) trials (Dapagliflozin Effect on CardiovasculAR Events (DECLARE-TIMI 58), Canagliflozin Cardiovascular Assess-ment Study (CANVA…
View article: Inhibition of the Sodium–Proton Antiporter (Exchanger) is a Plausible Mechanism of Potential Benefit and Harm for Drugs Designed to Block Sodium Glucose Co-transporter 2
Inhibition of the Sodium–Proton Antiporter (Exchanger) is a Plausible Mechanism of Potential Benefit and Harm for Drugs Designed to Block Sodium Glucose Co-transporter 2 Open
Clinical trials of sodium glucose co-transporter 2 inhibitors (SGLT2i) in patients with type 2 diabetes and comorbid cardiovascular and kidney disease have shown reductions in major adverse cardiovascular events, heart failure hospitalizat…